BEIJING — Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight-loss pill 'very soon', its CEO said on Tuesday (June 16), as it moves to catch up with rival Eli Lilly in the world's second-largest pharmaceutical market.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark on Dec 3, 2025.
BEIJING — Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight-loss pill "very soon", its CEO said on Tuesday , as it moves to catch up with rival Eli Lilly in the world's second-largest pharmaceutical market. Denmark's Novo and US-based Lilly believe weight-loss pills could attract patients reluctant to use injections and are racing to expand use of drugs that have transformed obesity treatment and reshaped the global pharmaceutical industry.
"We will be submitting oral Wegovy...for regulatory approval very soon... I would say a few months," Mike Doustdar, on his first visit to China since becoming Novo's CEO in August, told reporters. Competition in China has intensified in recent years, with Pfizer and local firms including Innovent Biologics entering the market. The patent for semaglutide, the active ingredient in Novo's blockbusters Wegovy and Ozempic, expired in China in March, though the company has regulatory data protection until early next year.
"One barrier to entry for the tablet will also be the scaling of this, in the way that we're able to do. And I would think not many of our competitors will be able to that level, have the capabilities," he said. Novo has received early approval in the US and Britain for its Wegovy pill and launched it in the US this year. In China, Lilly has moved first.
The company said in March it submitted a marketing application for once-daily orforglipron to the Chinese regulator at the end of 2025. The market share of weight-loss drugs in China is opaque, with firms including Innovent and Lilly not disclosing sales figures. Sales of GLP-1 treatments in China through major e-commerce platforms Alibaba and JD.com totalled about 1.4 billion yuan in the first quarter, according to Jefferies.
Please follow us on Google to support usSingapore Latest News, Singapore Headlines
Similar News: You can also read news stories similar to this one that we have collected from other news sources.
Myanmar's former junta chief kicks off visit to China as civilian presidentBEIJING — Myanmar's Min Aung Hlaing arrived in Beijing on Monday (June 15) for a five-day visit at the invitation of Chinese leader Xi Jinping, China's state media reported, marking his first trip to the world's second-largest economy since being elected president.
Read more »
China's dog meat trade sparks renewed debate over animal protection lawsA celebrity pet dog's reported theft and consumption has reignited debate in China over the country's dog meat trade, prompting renewed discussion about animal protection laws and shifting public attitudes over the practice.
Read more »
China, Myanmar pursue deeper ties as leaders hold talks in BeijingChinese President Xi Jinping held a bilateral meeting in Beijing with his Myanmar counterpart Min Aung Hlaing, Chinese official media agency Xinhua said on Tuesday (June 16), as the neighbouring countries seek to deepen relations.
Read more »
China's economic imbalance deepens as retail sales fall for first time in over three yearsBEIJING — China's economy showed increasing unevenness in May, with retail sales falling for the first time in over three years and investment slumping, while industrial output picked up pace.
Read more »